ClinicalTrials.gg
CompletedNCT04080713Updated Oct 21, 2019

Cortiment® MMX Pharmacokinetic Study

A Phase 1 interventional study of Budesonide in Healthy, sponsored by Ferring Pharmaceuticals. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-21.

Sponsored by Ferring Pharmaceuticals · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Budesonide is a well-known and well-characterised locally acting glucocorticosteroid with comparable efficacy to that of conventional glucocorticosteroids, but with fewer systemic side effects due to its low bioavailability following oral administration.

There are no benefits for subjects participating in this pharmacokinetic (PK) profile and safety study. This is an open-label study to investigate the PK profile and safety of single oral dose of budesonide prolonged release tablets (9 mg, Cortiment® MMX [multi-matrix system]) in healthy subjects in Indian population.

Two study visits are planned: One out-patient visit (screening) and one residential session consisting of three consecutive nights (admission to the clinical investigation unit at least 12 hours before dosing and discharge approximately 60 hours after dosing). End-of-study assessments will be performed before discharge from the clinical investigation unit in the single dosing period. Subjects should be in the fasted state for at least 10 hours pre-dose.

Number of subjects planned in total in the study are 24 men and women, with a minimum requirement of 7 women. The safety assessments comprise of adverse events (AEs), vital signs, electrocardiogram (ECG) and clinical laboratory variables. Adverse events will be collected throughout the study.

02

Conditions studied

  • Healthy

Keywords

  • Budesonide
  • Healthy
  • Pharmacokinetic
03

In context

Lead sponsor

Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Indian men and women between18-45 (both inclusive) years of age (at the time of signed/ thumb impression ).
  • (BMI) between 18.5 kg/m\^2 and 29.9 kg/m\^2 (both inclusive) and body weight between 50 kg and 100 kg.
  • Negative hepatitis screen including surface antigen (HBsAg) and/or virus (HCV) antibodies at screening.
  • Negative test result for (HIV) (I and II) antibody.
  • Healthy according to medical history (including surgical history), physical examination, 12-lead , chest X-ray recordings (postero-anterior view), vital sign (sitting blood pressure, pulse rate and body temperature), and laboratory profile of blood and urine at screening.
  • Negative serum pregnancy test (for females) at screening and on Day -1.
  • Regular intestinal function; no constipation and no diarrhea.
  • Has given written informed consent prior to any study-related activity is performed.
  • Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.
  • Negative alcohol test, urine drug screen test on the day of screening and the day before dosing.
  • Non-smokers.
  • Agree to use double-barrier or intra-uterine device, intra-uterine system, combined oral contraceptive pill associated with inhibition of ovulation (oral, intravaginal, transdermal), progesterone-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) during the study if not abstinent. Previous surgical sterilization of subject or their sexual partner (bilateral tubal ligation, vasectomy) also represents a permissible form of contraception. Methods of double barrier contraception include use of the male condom together with female condom or cervical cap or diaphragm.

Exclusion criteria

Exclusion Criteria:

  • Allergy: Ascertained or presumptive to the active principle, lecithin (derived from soya oil, peanut oil) and/or other formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study.
  • Diseases: Presence or relevant history of renal, hepatic, gastrointestinal (GI), cardiovascular, haematological, respiratory or any other body system, any recent or ongoing infections or endocrine or neurologic diseases that may interfere with the aim of the study. Particularly, history of GI diseases, inflammatory bowel disease (IBD), intolerance to lactose; neoplasias.
  • Medications: medication, including over-the-counter (OTC) and inducers/inhibitors or herbal medication, during 2 weeks or five half-lives of the drug, whichever is longer, prior to screening; in particular, drugs affecting GI physiology. Allowed medications included acetaminophen/paracetamol and cromoglycate eye drops according to label, hormonal for fertile women.
  • Previous or current budesonide treatment.
  • Use of within 4 weeks prior to dosing.
  • Life style: history (within the last two years) or present abuse of drug, alcohol [defined as regular intake of more than 14 units weekly for men /7 units weekly for women - one unit of alcohol equals about 300 mL of beer or lager, one glass (100 mL) of wine, or 25 mL spirits].
  • Current smokers or subjects who have smoked within last six months prior to start of the study.
  • Consumption of Grapefruits or its products within a period of one-week prior to receiving the study drug.
  • Consumption of poppy seeds (e.g., poppy cake) and betel nuts at least seven days at least seven days before receiving the trial drug.
  • A high daily consumption of caffeine-containing beverages (e.g., more than five cups of coffee or equivalent) with a risk of withdrawal. symptoms arising during the study that may have confounded the safety evaluation.
  • Female subjects who are pregnant, breastfeeding or intend to become pregnant.
  • Any medical or surgical condition that may interfere with the absorption, distribution, metabolism, or excretion of the drug, as judged by the investigator.
  • Acute illness within two weeks prior to screening.
  • Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.
  • Receipt of an medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication.

If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.

  • A mental condition, the lack of decision-making ability, dementia or a speech handicap, which, in the judgement of the Investigator, would impair the participation of the subjects in the study.
  • Any other reasons, which will make clinical study participation inappropriate with the decision of the investigator.
  • The presence of abnormal laboratory values during screening.
  • Difficulty in swallowing solids dosage forms like tablets or capsules.
  • Previous participation in a budesonide study.
  • History of diabetes and/or hyperglycemia.
  • History of menstrual disturbances (for females).
  • History of hypercorticism.
  • History of ophthalmological disorders (e.g. glaucoma).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Budesonide

    Drug: Budesonide

Interventions

  • Budesonide 9 mg prolonged release tablet

    Also known as: Cortiment® MMX

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum plasma concentration observed (Cmax)

    Time frame: Up to 60 hours post-dose

  2. Pharmacokinetics: Pharmacokinetic lag time (Tlag)

    Tlag is defined as the time of observation prior to the first observation with a measurable (non-zero) concentration.

    Time frame: Up to 60 hours post-dose

  3. Pharmacokinetics: Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 60 hours post-dose

  4. Pharmacokinetics: Area under the plasma concentration-time curve from time zero up to time t (AUCt)

    AUCt is defined as the area under the plasma concentration-time curve from time zero up to time t, where t is the last time point at which the concentration is above the lower limit of quantification (time of last measurable \[non-zero\] concentration \[tlast\]).

    Time frame: Up to 60 hours post-dose

  5. Pharmacokinetics: Area under the plasma concentration-time curve to infinity (AUCinf)

    Time frame: Up to 60 hours post-dose

  6. Pharmacokinetics: %Extrap AUC

    %Extrap AUC is defined as the percentage of AUC that is due to extrapolation from the last measurable concentration.

    Time frame: Up to 60 hours post-dose

  7. Pharmacokinetics: Terminal half-life (t1/2)

    Time frame: Up to 60 hours post-dose

  8. Pharmacokinetics: Terminal elimination rate constant (λz)

    λz is defined as the first-order rate constant associated with terminal (log-linear) portion of the plasma concentration-time curve estimated via linear regression of the time versus log concentration.

    Time frame: Up to 60 hours post-dose

  9. Pharmacokinetics: Apparent total systemic clearance (CL/F)

    Time frame: Up to 60 hours post-dose

  10. Pharmacokinetics: Apparent volume of distribution associated with the terminal phase (VZ/F)

    Time frame: Up to 60 hours post-dose

  11. Pharmacokinetics: Mean residence time (MRT)

    Time frame: Up to 60 hours post-dose

  12. Number of subjects with adverse events (AEs) and type of adverse events

    An AE is defined as any untoward medical occurrence in a subject taking part in a clinical study. Number of subjects with any AE (serious or non-serious) are presented.

    Time frame: From screening (Day-28 to Day -1) up to the end-of-study (Day 3)

  13. Number of subjects with abnormal laboratory parameters

    Number of subjects with abnormal findings in laboratory parameters (biochemistry, hematology, and urine analysis) will be presented.

    Time frame: From screening (Day-28 to Day -1) up to the end-of-study (Day 3)

  14. Number of subjects with abnormal vital signs

    Number of subjects with abnormal findings in vital signs will be presented.

    Time frame: From screening (Day-28 to Day -1) up to the end-of-study (Day 3)

  15. Number of subjects with abnormal changes in ECG

    Number of subjects with abnormal findings in ECG will be presented.

    Time frame: From screening (Day-28 to Day -1) up to the end-of-study (Day 3)

07

Study locations

1 site
  • Lambda Therapeutic Research Ltd
    Ahmedabad, Gujrat, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Sep 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 6, 2019
StartActual
Sep 16, 2019
Primary completionActual
Sep 25, 2019
CompletionActual
Sep 25, 2019
Last update
Oct 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04080713
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Sep 16, 2019
Primary completion
Sep 25, 2019
Completion
Sep 25, 2019
Last update
Oct 21, 2019

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion